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Introduction {#sec001}
============

*Plasmodium falciparum* (*P*. *falciparum*) is the most widespread *Plasmodium* species and is responsible for the majority of severe forms and deaths related to malaria in sub-Saharan Africa. *P*. *falciparum* has succeeded in developing resistance mechanisms against almost all existing antimalarial drugs, which is a major threat to malaria control worldwide. The high level of *P*. *falciparum* resistance to chloroquine (CQ) and then to sulfadoxine-pyrimethamine (SP) has led endemic countries to change their antimalarial drug policy of uncomplicated malaria treatment. In the Democratic Republic of Congo (DRC), Artemisinin-based Combination Therapies (ACTs) have been adopted as first-line treatment of uncomplicated malaria in 2005 \[[@pone.0237791.ref001]\]. With the discovery of several *P*. *falciparum* genes involved in antimalarial drug resistance, molecular markers have become a precious tool in resistance surveillance \[[@pone.0237791.ref002], [@pone.0237791.ref003]\]. Mutations in the propeller domain of *P*. *falciparum* Kelch 13 gene (*pfk13)* have been identified as associated with in-vivo delayed parasite clearance and in-vitro artemisinin resistance (ART-R) in ring stage survival Assay (RSA) \[[@pone.0237791.ref004], [@pone.0237791.ref005]\]. These mutations spread into the Greater Mekong Sub-region (GMS) of Southeast Asia \[[@pone.0237791.ref006], [@pone.0237791.ref007]\] and have been recently classified in validated markers of ART-R (F446I, N458Y, M476I, Y493H, R539T, I543T, P553L, R561H and C580Y) and candidate/associated markers of ART-R (P441L, G449A, C469F, A481V, P527H, N537I, G538V, V568G, P574L, F673I, A675V) \[[@pone.0237791.ref008]\]. In Sub-Saharan Africa, there has been no evidence for emergence of *Pf* ART-R until now. Mutations detected in Africa have not been associated to ART-R like those reported in Southeast Asia \[[@pone.0237791.ref006], [@pone.0237791.ref007], [@pone.0237791.ref009]--[@pone.0237791.ref011]\]. Some mutations associated with slow parasite clearance detected in Africa have been reported with very low relative frequency \[[@pone.0237791.ref012]--[@pone.0237791.ref014]\]. The spread of ART-R from the GMS to Africa, like previously happened with other antimalarial drugs \[[@pone.0237791.ref015], [@pone.0237791.ref016]\], may be a major obstacle for malaria control and elimination around the World.

In DRC, like in almost all Sub-Saharan countries, none of validated ART-R mutations detected in Southeast Asia has been found. However, the S522C mutation which has been described to be associated with delayed clearance but without statistical significance \[[@pone.0237791.ref008]\], has been detected by a previous study in one isolate in DRC \[[@pone.0237791.ref017]\]. To continue monitoring, this study investigated the *pfk13*-propeller polymorphisms in clinical isolates of *P*. *falciparum* collected across the DRC.

Materials and methods {#sec002}
=====================

Study area {#sec003}
----------

Ten sites were selected among the 26 provinces of the DRC. The study included the 3 largest cities of the country (Kinshasa, Kisangani and Lubumbashi) as well as 7 other sites that were selected based on their epidemiological facies of malaria: Bolenge, Karawa and Vanga for the equatorial facies, Kalima, Kamina and Fungurume for the tropical facies and Katana for the mountainous facies. All selected sites are National Malaria Control Program (NMCP) sentinel sites for malaria surveillance, including Kingasani in Kinshasa and Kabondo in Kisangani, except Lubumbashi. These sites are organized within one selected Health Zone entity, per province and are part of a national network for malaria surveillance. In each study site, 4 to 5 health structures were selected based on the accessibility and the attendance for the realization of the study. A pilot study was conducted first at Kingasani in Kinshasa from January to March 2017. Afterwards, the study was started in the other sites from September to December 2017.

Study participants {#sec004}
------------------

Patients of all ages presenting at study site for fever and who had a positive rapid diagnostic test (RDT) or a positive thick blood smear for malaria were enrolled after informed consent was given.

Blood sample collection {#sec005}
-----------------------

Screening tests were performed on blood samples taken by finger prick. The SD Bioline Malaria Ag Pf (Standard Diagnostics) assay was used to enroll patients attending all collection sites. However, in Kinshasa, the CareStart Malaria Pf (Access Bio) was also used. In case of lack of RDTs, a positive thick blood smear for malaria was used for enrollment.

After enrollment, a blood sample was taken by finger prick and three spots were deposited on Whatman Grade GB003 filter paper (Whatman/GE Healthcare). Dried blood spots (DBS) were placed in an individual ziploc plastic bag containing silicagel desiccant and were then stored at room temperature before their transfer to the laboratory of the Department of Clinical Microbiology (University of Liège) for molecular analysis.

DNA extraction {#sec006}
--------------

DNA was extracted from blood spots by using the QIAamp DNA Mini Kit (Qiagen, Germany) following the recommended protocol for DBS. The extracted DNA was stored at-- 20°C before PCR testing.

*P*. *falciparum* real-time PCR {#sec007}
-------------------------------

A real-time PCR for the detection of *P*. *falciparum* was performed according to a modified procedure previously described \[[@pone.0237791.ref018]\], as follows: 200 nM of *P*. *falciparum* primers and probe, a volume of 2.5 μl of Double-Dye Probe/Primer for Internal Positive Control (IPC), 2.5 μl of DNA virus culture (DIA-EIC/DNA(Cy5) for IPC, 12.5 μl of 2X Taqman Universal PCR Master Mix (Applied Biosystems) and water to make a final volume of 25 μl including 5 μl of DNA sample. Assays were run on an ABI 7500 Fast real-time thermocycler (Applied Biosystems).

*pfk13* PCR {#sec008}
-----------

A conventional PCR was developed at the Laboratory of Clinical Microbiology of University hospital of Liege using *P*.*falciparum* strains W2, 3D7 and IPC 3445 obtained from parasite culture and clinical isolates from patients with *P*. *falciparum* malaria. The PCR-amplified sequence consisted of a 506-nucleotide fragment of the *pfk13*-propeller gene (containing codons 427--595) which included recently described mutations associated with ART-R \[[@pone.0237791.ref008]\]. The forward primer ArtprdF: `5’-ACTGTAAAACGACGGCCAGTCCATTAGTTCCACCAATGACA-3’` and reverse primer ArtprdR: `5’-ACCAGGAAACAGCTATGACCAGCCTTGTTGAAAGAAGCAGA-3’` were designed and used in a reaction mixture containing 0.4μM of each primer, 10μl of LightCycler^R^ Multiplex DNA Master 5X version 6 (Roche Diagnostics GmbH, Germany), 10μl of genomic DNA, and water to make a final volume of 50μl. The PCR was run on a conventional Dyad Peltier Thermal Cycler (Bio-Rad Laboratories, CA, US) according to the following cycling parameters: Initial denaturation at 95° C for 9 minutes followed by 10 cycles of a denaturation at 95°C for 30 sec, an annealing at 43°C for 1 min, an extension at 72°C for 1 min, followed by 35 cycles of a denaturation at 95°C for 30 sec, an annealing at 60°C for 1 min, an extension at 72°C for 1 min and a final extension at 72°C for 5 min. The PCR products were visualized after electrophoresis on 2% agarose gel stained with ethidium bromide.

*pfk13* genotyping {#sec009}
------------------

After purification using AMPure XP magnetic beads (Beckman Coulter, CA, US), the PCR products were added to a mix of Big Dye Terminator V3.1 for the sequencing reaction. The resulting 506-bp nucleotide sequences were analysed on an ABI 3730 DNA Analyzer automated sequencer (Applied Biosystems) using the Sanger method at GIGA (University of Liège's interdisciplinary research institute in the biomedical sciences). These 506-bp sequences (forward and reverse) of the *pfk13* gene encompassing the codons at position 427--595, were aligned using Vector NTI (Thermo Fisher Scientific, US) and compared to the reference sequence PF3D7_1343700 ([http://www.plasmodb.org](http://www.plasmodb.org/), accessed on May 6, 2019) using the online Basic Local Alignment Search Tool (BLAST) (National Center for Biotechnology Information-NCBI) for identifying mutations. Sequences have not been deposited in any data repository.

Ethical considerations {#sec010}
----------------------

The protocol and the informed consent received approbation from the Ethics Committee of the Faculty of Medicine, University of Kinshasa (approval N°: ESP MINESU 019/2016). All the participants including parents or guardians of children involved in the study signed an informed consent.

Statistical analysis {#sec011}
--------------------

Data were entered in a 2010 Excel sheet by an independent data clerk. Statistical analysis was performed using SPSS V. 20.0 (IBM corp, Armonk, NY). Samples for which genotype profile could not be determined were excluded from the analysis. Categorical variables were expressed as frequencies with 95% confidence intervals (95% CI). The mutant and wild-type alleles identified in the sequenced isolates were used to generate the prevalence of the alleles.

Results {#sec012}
=======

A total of 1070 patients were enrolled in the study, their median age was 7 years (IQR 3--18 years) and the male to female sex ratio was 0.94.

Real-time PCR analysis performed on DNA extracted from DBS confirmed the initial diagnosis of *P*. *falciparum* infection for 806 (75.3%; 95% CI: 72.6%-- 77.9%) patients. Of the 717 successfully sequenced *P*. *falciparum* isolates, 710 (99.0%; 95% CI: 97.9% - 99.6) were wild-type and 7 (1.0%; 95% CI: 0.4% - 2.1%) carried non-synonymous (NS) mutations in *pfk13*-propeller among which 2 previously described (A578S, V534A) and 2 mutations not yet described (M472I, A569T) in the DRC. A578S mutation was detected in 4 study sites while M472I, V534A and A569T were found only in one site each, as shown in [Table 1](#pone.0237791.t001){ref-type="table"}.

10.1371/journal.pone.0237791.t001

###### Polymorphisms in *pfk13-*propeller per study site.

![](pone.0237791.t001){#pone.0237791.t001g}

  Site         Positive RDT or thick blood samples N   Positive *Pf* PCR samples N   Positive Pf PCR % (95% CI)   *Pf* PCR + successfully sequenced samples N   Mutant-type parasites N   Mutant-type parasites % (95% CI)   NS Mutation
  ------------ --------------------------------------- ----------------------------- ---------------------------- --------------------------------------------- ------------------------- ---------------------------------- -------------
  Bolenge      98                                      73                            74.5 (64.7--82.8)            63                                            1                         1.6 (0.0--8.5)                     A578S
  Fungurume    92                                      65                            70.7 (60.2--79.7)            60                                            1                         1.7 (0.0--8.9)                     A578S
  Kalima       97                                      67                            69.1 (58.9--78.1)            67                                            0                         0.0 (0.0--5.4)                     \-
  Kamina       98                                      73                            74.5 (64.7--82.8)            72                                            1                         1.4 (0.0--7.5)                     A569T
  Karawa       97                                      66                            68.0 (57.8--77.1)            64                                            0                         0.0 (0.0--5.6)                     \-
  Katana       105                                     78                            74.3 (64.8--82.3)            73                                            1                         1.4 (0.0--7.4)                     M472I
  Kinshasa     160                                     160                           100 (100.0--100.0)           100                                           1                         1.0 (0.0--5.4)                     A578S
  Kisangani    128                                     93                            72.7 (64.1--80.2)            92                                            1                         1.1(0.0--5.9)                      A578S
  Lubumbashi   101                                     56                            55.4 (45.2--65.3)            53                                            0                         0.0 (0.0--6.7)                     \-
  Vanga        94                                      75                            79.8 (70.2--87.4)            73                                            1                         1.4 (0.0--7.4)                     V534A
  Total        1070                                    806                           75.3 (72.6--77.9)            717                                           7                         1.0 (0.4--2.1)                     

N: Number; *Pf*: *Plasmodium falciparum*, PCR: Polymerase chain reaction, RDT: Rapid diagnostic test; NS: Non-synonymous.

In addition, the distribution of mutations per age range of patients showed the presence of A578S in all age ranges ([Table 2](#pone.0237791.t002){ref-type="table"}).

10.1371/journal.pone.0237791.t002

###### Distribution of mutations per age range of patients.

![](pone.0237791.t002){#pone.0237791.t002g}

  NS mutation   Age range (years)               
  ------------- ------------------- --- --- --- ---
  M472I         1                   0   0   0   1
  V534A         1                   0   0   0   1
  A569T         0                   0   1   0   1
  A578S         1                   1   1   1   4
  Total         3                   1   2   1   7

Discussion {#sec013}
==========

The present study was conducted in ten sites across DRC for assessing the prevalence of polymorphisms in *pfk13*-propeller gene related to ART-R. We report that 99.0% of *P*. *falciparum* isolates were wild-type alleles and none of ART-R mutations found in Southeast Asia has been detected among the 1.0% of isolates carrying NS mutations.

Previous studies reported very limited polymorphisms in *Pfk13* ranging from 0 to 3% in the DRC and others African countries including Rwanda, Gabon, Cameroun, Republic of Congo, Angola \[[@pone.0237791.ref012], [@pone.0237791.ref014], [@pone.0237791.ref019]--[@pone.0237791.ref021]\]. In the present study, seven *P*. *falciparum* isolates carried NS mutations among which A578S in 4 isolates and A569T, M472I and V534A in 1 isolate each. In a worldwide survey published in 2016, reporting 14 NS mutations in the DRC, 3 (21.4%) A578S and 3 (21.4) V534A were characterized while A569T and M472I were not found in the DRC but reported in Rwanda (1/5) and in Niger (1/8) respectively \[[@pone.0237791.ref006]\]. A578S is commonly detected in Sub-Saharan African countries \[[@pone.0237791.ref006], [@pone.0237791.ref007], [@pone.0237791.ref009], [@pone.0237791.ref011]\] and has also been reported out of Africa such as in Thailand and Bangladesh \[[@pone.0237791.ref022]\]. The survey cited above reported 41 A578S mutations in Africa out of a total of 42 worldwide. A578S is of interest for several reasons: 1) it is the most frequent mutation detected in 4 study sites (Kinshasa, Bolenge, Kisangani and Fungurume) and in all age ranges; 2) it is located 2 amino acids upstream of the C580Y Single Nucleotide Polymorphism (SNP), which is one of the mutations involved in ART-R and associated with 85% of the ART treatment failure in Southeast Asia \[[@pone.0237791.ref006]\]; 3) in this mutation, a neutral nonpolar amino acid (A) is replaced with a neutral but polar amino acid (S). Computational modeling and a mutational sensitivity prediction suggest that the A578S SNP could disrupt the function of *pfk13*-propeller \[[@pone.0237791.ref022]\]. However, some studies have shown that the A578S mutation was associated neither with slow parasite clearance nor with reduced in-vitro ART susceptibility \[[@pone.0237791.ref005], [@pone.0237791.ref006]\]. The effect of this mutation mostly detected in parasites from Africa remains unknown, additional local studies are needed to clarify the significance of this NS substitution.

Three other mutations with unknown effects were found in the present study, notably M472I, V534A and A569T. M472I has been detected in 1 isolate in Katana site located in Sud-Kivu province in the eastern part of country. In this mutation, Methionin (M) is replaced by Isoleucin (I) at position 472 in PFK13 protein. A Similar coding substitution is observed 4 amino acids downstream of an ART-R validated marker namely M476I \[[@pone.0237791.ref008]\]. The M472I mutation not far from M476I could also alter the function of the *pfk13* gene with implication in resistance to ART. The M476I mutation was first observed in a Tanzanian strain (F32-ART) built from parasites that were exposed in vitro to increasing concentrations of ART \[[@pone.0237791.ref005]\], afterward, it has been found in a patient in Tanzania \[[@pone.0237791.ref013]\]. The Katana site corresponds to the mountainous facies in which a lower malaria transmission rate results in drug resistant genotypes not being broken down due to less sexual recombination occurring. Drug resistance appears and emerges from this kind of places as previously shown in South-East Asia, considered as the bastion of antimalarial resistance \[[@pone.0237791.ref023]\]. Such a suspicious mutation found in the eastern part of DRC should be a signal for continuous surveillance because it has been suggested that in Africa, antimalarial drug resistance has historically risen in the East and spreads to the rest of the continent \[[@pone.0237791.ref024]\]. In addition, political instability in the East of the country is an obstacle to good management of the use of antimalarial drugs as recommended by the national policy. V534A which was previously detected in the DRC (3 out of 14 NS mutations) and A569T previously found elsewhere (1 out of 5 NS mutations in Rwanda) \[[@pone.0237791.ref006]\], should also call for further surveillance studies. Although the frequency of wild-type *pfk13*-propeller genes was highly predominant, we observed three coding substitutions that are of unknown phenotype. Numerous other coding substitutions of unclear phenotype have been reported in several African countries such as in Tanzania, Cameroun and Kenya \[[@pone.0237791.ref013], [@pone.0237791.ref025], [@pone.0237791.ref026]\]. Additional information, not assessed by the present study, such as the clinical and parasitological responses to malaria treatment in enrolled patients could help for a better interpretation of the biological and clinical impact of these mutations. There are criteria for prioritizing further laboratory studies notably the frequent observation of a new allele with a non-synonymous mutation, the evidence of dissemination and preliminary association with clinical data whenever possible \[[@pone.0237791.ref006], [@pone.0237791.ref007]\].

Several independent single nucleotide polymorphisms (SNPs) could be responsible of the ART-R in Sub-Saharan Africa, ongoing molecular surveillance will need to detect the presence of new mutations, shifts in frequencies of existing African genotypes, and the importation of Southeast-Asian resistance mutations. The known SNPs that confer drug resistance would differ from one location to another, depending on the parasite genetics. There is the possibility that *pfk13* mutations do not cause ART-R in isolation but would act in combination with other genetic or non-genetic factors that are different in African and Southeast Asia parasite populations \[[@pone.0237791.ref009], [@pone.0237791.ref027]\]. Since African *pfk13*-propeller mutations were shown to be different from those found in Southeast Asia, further molecular and biochemical studies should investigate whether other factors such as additional mutations could be associated to alter the functions of PFK13 protein, resulting in altered ART sensibility.

Routine monitoring and surveillance of ART resistance, as recommended by WHO, should be continuously strengthened to ensure the effectiveness of anti-malarial drugs in use. In the DRC, the national policy supports two first-line ACT treatments: artesunate-amodiaquine (AS/AQ) and artemether-lumefantrine (AL) for uncomplicated malaria. If one of the two first-line ACTs is not available or is poorly tolerated by the patient, the other one can be used. In case of confirmed treatment failure by microscopy to both first-line ACTs, the patient should be given dual therapy of quinine plus clindamycin. For treatment of severe malaria, injectable artesunate should be the first treatment option, followed by injectable artemether or intravenous quinine \[[@pone.0237791.ref028]\]. This study contributes to the ongoing surveillance of ART resistance in the DRC. However, a broader scope in *pfk13 gene* would have been desirable to explore all candidate and probable markers of ART resistance previously described \[[@pone.0237791.ref006], [@pone.0237791.ref007]\].

Conclusion {#sec014}
==========

Mutations associated with ART-R in Southeast Asia were not observed in the DRC. However, the appearance of coding substitutions that are of unknown phenotype calls for further investigations. Routine monitoring must continue in order to ensure that the recommended ACTs are effective, that timely changes to national treatment policies can be implemented, and that ART-R can be detected early.

Supporting information {#sec015}
======================

###### Minimal data set containing supporting information (raw data) for study findings in different study parameters (site, age, sex, RDT result, P. falciparum PCR result, K13-propeller polymorphism).

(XLSX)

###### 

Click here for additional data file.

###### Nucleotide sequences for *Plasmodium falciparum* isolates successfully sequenced (wild and mutants).

(XLSX)

###### 

Click here for additional data file.
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2\. The authors have used a Taqman based qPCR assay for P.falciparum detection. As such, it would be good if qPCR based parasite quantification data is mentioned in the results. It would be especially interesting to learn about the difference and correlation (if any) in the parasite counts in individuals harbouring wild-type versus mutant K-13 isolates.

3\. No mention is made of the patient demographics in the manuscript. Any possible association between patient demographics and isolation of mutant parasite strains should be looked into and included in the results.

Minor issues

1\. Since drug resistance mutations often have a tendency to cluster together, it would be good to know if the isolates harbouring K-13 mutations also have other antimalarial drug mutations. If these isolates have been subjected to such tests, the information should be included in the results.

2\. The sequenced isolates do not mention any accession numbers. If these sequences have not been deposited in any data repository, the information should be included in the methodology.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Myat Htut Nyunt

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Responses to Reviewers

Reviewer \#1:

We thank the reviewer very much for the comments, which helped us improving the manuscript.

\- Tile: Consider to revise the title and running title to cover the whole picture of the study. Eg, Lack of K13..... in Congo. Running title: Pf K13 polymorphism in DROC.

A/ Thank you for the suggestion. We've revised the title and running title.

\- Line 43, M472I, V534A and A569T are not new mutation. These are already reported. (DOI: 10.9734/JAMMR/2017/34192) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955562/> (Major comment) If you want to say these are new SNPs detected in DRC, clearly mention in abstract also.

A/ Thank you for pointing this out. We've corrected in the manuscript: we've removed the term \"new\" and preferred say \"previously detected and not yet detected in DRC\"

\- The author use the term \"novel mutation\" for SNP detected that were not reported before in DRC. But these SNPs are already reported in other areas. It means it is not novel mutation. Correct the term used in the paper. (Figure also for \"new mutation\")

A/ Thank you for the remark. We've corrected in the whole text.

\- In discussion, among the previous reported SNP, number as well as percentage should be shown.

A/ Thank you for the suggestion. We've added number and percentage for previous reported SNP.

\- The authors also used the term \"New developed pfk13 PCR\" for newly designed primer. It is also not need to mention the term \"new developed\" that is for new innovative procedures that is not reported elsewhere.

A/ Thank you for the remark. We've removed the term \"New\"

\- Here again, why the authors do not use the previously published primers set? Describe it. Moreover, the primers used in this study cover only codons 427 -- 595. So, it will miss the SNP beyond the aa 595 in K13 propeller gene. A676 and H719 were also interesting SNPs and reported. The authors need to describe the rationale for it.

A/ Thank you for the comment. We've designed new primers to amplify a segment containing all validated mutations and majority of candidate mutations associated to artemisinin resistance. We've taken into account the limit size (700-800bp) of segment to ensure a better quality of sequences obtained from Sanger sequencing method used in this study. A broader view would have been desirable to explore other candidate mutations. We've mentioned this limitation in discussion section.

\- It is better to include the basic demographic character of the participants as well as the clinical data of day3 positivity (if possible)

A/ Thank you for the suggestion. We've included in the results the repartition of participants per age range and per sex. Clinical follow-up data were not assessed by the study.

\- Describe the first line and second line treatment for pf in Congo in Discussion.

A/ Thank you for the suggestion. We've include an overview of first-line and second-line treatment used in DRC for uncomplicated malaria in the discussion section.

Reviewer \#2:

1\. Summary of the research

Yobi et.al have looked at polymorphisms in the Kelch 13 propeller gene in P.falciparum isolates from clinical samples in the DRC and have reported both existing and new non-synonymous mutations in the gene from the region; although none of these mutations have been directly implicated in ART resistance. The study has been conducted with comprehensive coverage of the major malaria endemic regions of the country with an adequate sample size. The diagnostics and methodology are robust and the results are expressed in a logical manner. Given the fact that artemisinin is the mainstay for treatment for uncomplicated falciparum malaria, monitoring its activity is important in the field and in this regard, the authors have looked into K-13 mutations which is a preliminary molecular marker for possible artemisinin resistance.

We sincerely thank the reviewer for these very encouraging comments and remarks to improve this work.

2\. Examples and evidence

Major issues

1\. The authors have looked into K-13 polymorphisms within a limited codon range (427-595). Although most of the validated K-13 propeller mutations associated with ART resistance are covered in this range, a broader scope could have been adopted to cover other candidate mutations. Since ART resistance is still evolving in Africa, a comprehensive investigation into all established and probable markers of ART resistance would have given a clearer picture of the situation.

A/ Thank you for the comment. As you said, we've amplified a segment containing all validated mutations and majority of candidate mutations associated to artemisinin resistance. We've taken into account the limit size (700-800bp) of segment to ensure a better quality of sequences obtained from Sanger sequencing method used in this study. A broader view would have been desirable to explore other candidate mutations. We've mentioned this limitation in discussion section.

2\. The authors have used a Taqman based qPCR assay for P.falciparum detection. As such, it would be good if qPCR based parasite quantification data is mentioned in the results. It would be especially interesting to learn about the difference and correlation (if any) in the parasite counts in individuals harbouring wild-type versus mutant K-13 isolates.

A/ Thank you for the suggestion. In this study, we did not quantify parasite densities in participants, we've just noted the presence or not of the Plasmodium falciparum. We will take this suggestion into account in our future studies.

3\. No mention is made of the patient demographics in the manuscript. Any possible association between patient demographics and isolation of mutant parasite strains should be looked into and included in the results.

A/Thank you for the suggestion. We've included in results the distribution of patients per age range and per sex and the distribution of mutations per age range of patients.

Minor issues

1\. Since drug resistance mutations often have a tendency to cluster together, it would be good to know if the isolates harbouring K-13 mutations also have other antimalarial drug mutations. If these isolates have been subjected to such tests, the information should be included in the results.

A/ Thank you for pointing this out. Other antimalarial drug mutations including mutations on pfcrt gene associated with chloroquine resistance were addressed in another paper.

2\. The sequenced isolates do not mention any accession numbers. If these sequences have not been deposited in any data repository, the information should be included in the methodology.

A/ Thank you for pointing this out. We've mentioned in Methods section the sequences were not deposited in any data repository.
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The lack of K13-propeller mutations associated with artemisinin resistance in Plasmodium falciparum in Democratic Republic of Congo (DRC)

PLOS ONE

Dear Dr. Yobi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

I would request the authors to revise the Table 1 as suggested by reviewer 1 before a final decision can be is taken

==============================

Please submit your revised manuscript by Aug 28 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Md Atique Ahmed, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Please address Reviewer 1 comments before a final decision is taken.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Table 1. Efficacy should be \"frequency or number of the cases\" If you have no hypothesis on ART based on sex, you should not compare between male and female. If you have hypothesis, you can compare and statistical analysis will be needed. For my opinion, you can simply describe basic demographic character of the participants (eg Age mean(SD), M:F, region etc only.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237791.r004
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Reviewer \#1:

We sincerely thank the reviewer for the suggestion, raised to improve the quality of the manuscript.

Q/ Table 1. Efficacy should be \"frequency or number of the cases\" If you have no hypothesis on ART based on sex, you should not compare between male and female. If you have hypothesis, you can compare and statistical analysis will be needed. For my opinion, you can simply describe basic demographic character of the participants (eg Age mean(SD), M:F, region etc only

A/ Based on the suggestion by the reviewer, we've opted to describe basic demographic characters of the participants (median age, sex ratio) only in the text of the manuscript in place of the table. The distribution of K13 polymorphim per region (site) of participants can be found in table 1 of the newly revised version.
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Dear Dr. Yobi,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Md Atique Ahmed, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0237791.r006

Acceptance letter

Ahmed

Md Atique

Academic Editor

© 2020 Md Atique Ahmed

2020

Md Atique Ahmed

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

11 Aug 2020

PONE-D-20-05168R2

The lack of K13-propeller mutations associated with artemisinin resistance in *Plasmodium falciparum* in Democratic Republic of Congo (DRC)

Dear Dr. Yobi:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff
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Dr. Md Atique Ahmed
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